EORTC 22996-24002/TROG 01.01 - EPO Head & Neck

By w.paterson
14 August, 2021
0 Comments

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma

Primary Sponsor

EORTC

Collaborating Groups

TROG Cancer Research

5 December, 2024

Extended follow-up of TROG 99.03 lymphoma trial published

5 December 2024: Study shows huge improvement in progression-free

28 November, 2024

Meet TROG President: A/Prof Puma Sandaresan

28 November 2024: In this Q&A, TROG President A/Prof

Register for the 2025 ASM

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma

EORTC/TROG 01.03 – Glioblastoma/Temozolomide – 26981/22981

TROG 99.06 – Bladder (Phase II)

Related Post

Extended follow-up of TROG 99.03 lymphoma trial published

Meet TROG President: A/Prof Puma Sandaresan

Register for the 2025 ASM

EORTC 22996-24002/TROG 01.01 – EPO Head & Neck

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma

EORTC/TROG 01.03 – Glioblastoma/Temozolomide – 26981/22981

TROG 99.06 – Bladder (Phase II)

Related Post

Extended follow-up of TROG 99.03 lymphoma trial published

Meet TROG President: A/Prof Puma Sandaresan

Register for the 2025 ASM